---
title: "Repatha (evolocumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Repatha (evolocumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: What type of drug is Repatha? How does Repatha work (mechanism of action)? How quickly does Repatha lower LDL cholesterol? What is the half-life of Repatha? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/repatha/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Repatha (evolocumab), all indications: Pharmacology questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)  
Indication pages: [Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)

## Mechanism

<a id="repatha-drug-class"></a>

### What type of drug is Repatha?

> “REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) 
> inhibitor”

Source: [REPATHA: Prescribing information, page 1, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=1)

> “Evolocumab is a human monoclonal immunoglobulin G2 (IgG2) directed against human proprotein 
> convertase subtilisin kexin type 9 (PCSK9). Evolocumab has an approximate molecular weight (MW) of 
> 144 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.”

Source: [REPATHA: Prescribing information, page 9, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=9)

<a id="repatha-mechanism"></a>

### How does Repatha work (mechanism of action)?

> “Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin 
> type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptor (LDLR) on the surface of 
> hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to 
> LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby 
> lowering LDL-C levels.”

Source: [REPATHA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=10)

> “Normally, PCSK9 binds to the LDL receptor (LDLR) on the surface of hepatocytes, leading to the degradation of the LDLR and higher LDL-C levels.
>
> Repatha<sup>®</sup> enhances removal of LDL-cholesterol by inhibiting PCSK9, increasing the number of LDL receptors on the surface of the liver, resulting in reduction of LDL-C from circulation.”

Source: [REPATHA: Mechanism of Action (MOA), captured 2026-11-13](https://www.repathahcp.com/mechanism-of-action#:~:text=Normally%2C%20PCSK9%20binds%20to%20the,reduction%20of%20LDL%2DC%20from%20circulation.)

<a id="repatha-ldl-onset"></a>

### How quickly does Repatha lower LDL cholesterol?

> “Following single subcutaneous administration of 140 mg or 420 mg of evolocumab, maximum 
> suppression of circulating unbound PCSK9 occurred by 4 hours. Unbound PCSK9 concentrations 
> returned toward baseline when evolocumab concentrations decreased below the limit of quantitation. 
> Maximum LDL-C reduction occurred by 2 weeks after a single-dose of 140 mg of evolocumab and by 
> 3 weeks after a single-dose of 420 mg of evolocumab.”

Source: [REPATHA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=10)

> “Assess LDL-C when clinically appropriate. The LDL-lowering effect of REPATHA may be 
> measured as early as 4 weeks after initiation.”

Source: [REPATHA: Prescribing information, page 2, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=2)

## Pharmacokinetics

<a id="repatha-half-life"></a>

### What is the half-life of Repatha?

> “REPATHA was 
> estimated to have an effective half-life of 11 to 17 days.”

Source: [REPATHA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=10)

> “An approximate 2- to 3-fold accumulation was observed in 
> trough serum concentrations (Cmin 7.21 µg/mL) following 140 mg doses administered subcutaneously 
> every 2 weeks or following 420 mg doses administered subcutaneously monthly (Cmin 11.2 µg/mL), and 
> serum trough concentrations approached steady-state by 12 weeks of dosing.”

Source: [REPATHA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=10)

> “Following a single subcutaneous dose of 140 mg or 420 mg evolocumab administered to healthy adults, 
> median peak serum concentrations were attained in 3 to 4 days, and estimated absolute bioavailability was 
> 72%.”

Source: [REPATHA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=10)

<a id="repatha-elimination"></a>

### How is Repatha metabolized and eliminated?

> “Two elimination phases were observed for REPATHA. At low concentrations, the elimination is 
> predominately through saturable binding to target (PCSK9), while at higher concentrations the 
> elimination of REPATHA is largely through a non-saturable proteolytic pathway.”

Source: [REPATHA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=10)

> “Since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not 
> expected to impact the pharmacokinetics of evolocumab.”

Source: [REPATHA: Prescribing information, page 11, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=11)

## Components

<a id="repatha-inactive-ingredients"></a>

### What are the inactive ingredients in Repatha?

> “REPATHA is a sterile, preservative-free, clear to opalescent, colorless to pale yellow solution for 
> subcutaneous use. Each 1 mL prefilled single-dose pen, prefilled single-dose SureClick<sup>®</sup> autoinjector and 
> prefilled single-dose syringe contains 140 mg evolocumab, acetate (1.2 mg), polysorbate 80 (0.1 mg), 
> proline (25 mg) in Water for Injection, USP. Sodium hydroxide may be used to adjust to a pH of 5.0.”

Source: [REPATHA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=10)

## Related pages
- [Medical information: Repatha (evolocumab): All indications](https://www.evicenter.com/medical-information/repatha)
- [Indication](https://www.evicenter.com/medical-information/repatha/indication)
- [Safety](https://www.evicenter.com/medical-information/repatha/safety)
- [Specific populations](https://www.evicenter.com/medical-information/repatha/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/repatha/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/repatha/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/repatha/access-and-coverage)
